Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Kintara Therapeutics stock

Learn how to easily invest in Kintara Therapeutics stock.

Kintara Therapeutics is a biotechnology business based in the US. Kintara Therapeutics shares (KTRA) are listed on the NASDAQ and all prices are listed in US Dollars. Kintara Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Kintara Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – KTRA. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Kintara Therapeutics stock price (NASDAQ: KTRA)

Use our graph to track the performance of KTRA stocks over time.

Kintara Therapeutics shares at a glance

Information last updated 2023-01-26.
Latest market close$6.56
52-week range$3.50 - $24.90
50-day moving average $7.25
200-day moving average $8.87
Wall St. target price$150.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.64

Buy Kintara Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Kintara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kintara Therapeutics price performance over time

Historical closes compared with the close of $6.56 from 2023-01-27

1 week (2023-01-23) 8.25%
1 month (2022-12-30) -4.79%
3 months (2022-10-28) 5,809.91%
6 months (2022-07-29) 3,370.90%
1 year (2022-01-28) 1,654.01%
2 years (2021-01-29) 264.44%
3 years (2020-01-30) 1,057.78%
5 years (2018-01-30) 396.97%

Kintara Therapeutics financials

Gross profit TTM $0
Return on assets TTM -75.09%
Return on equity TTM -147.95%
Profit margin 0%
Book value $-1.82
Market capitalisation $9.3 million

TTM: trailing 12 months

Kintara Therapeutics share dividends

We're not expecting Kintara Therapeutics to pay a dividend over the next 12 months.

Have Kintara Therapeutics's shares ever split?

Kintara Therapeutics's shares were split on a 1:50 basis on 13 November 2022. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kintara Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Kintara Therapeutics shares which in turn could have impacted Kintara Therapeutics's share price.

Kintara Therapeutics share price volatility

Over the last 12 months, Kintara Therapeutics's shares have ranged in value from as little as $3.5022 up to $24.895. A popular way to gauge a stock's volatility is its "beta".

KTRA.US volatility(beta: 1.04)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kintara Therapeutics's is 1.0415. This would suggest that Kintara Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Kintara Therapeutics overview

Kintara Therapeutics, Inc. , a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China.

Frequently asked questions

What percentage of Kintara Therapeutics is owned by insiders or institutions?
Currently 6.298% of Kintara Therapeutics shares are held by insiders and 4.64% by institutions.
How many people work for Kintara Therapeutics?
Latest data suggests 3 work at Kintara Therapeutics.
When does the fiscal year end for Kintara Therapeutics?
Kintara Therapeutics's fiscal year ends in June.
Where is Kintara Therapeutics based?
Kintara Therapeutics's address is: 9920 Pacific Heights Blvd, San Diego, CA, United States, 92121
What is Kintara Therapeutics's ISIN number?
Kintara Therapeutics's international securities identification number is: US49720K1016

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site